888MO Effectiveness of brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma: A systematic review and meta-analysis

Abstract

84.6%) patients completed six cycles of therapy, 142 (66.6%) underwent interim PET2, of which 30.4% were positive, however few (n¼ 25, 17.6%) had PET-adapted modifications. A majority (89.1%) of patients received at least one supportive care product. AEs were more prevalent among older patients (>60 years). All grade neutropenia occurred in 47.1% of the patients receiving ABVD; the rate of febrile neutropenia was 6.8%. Other AEs included: infections (22.2%), anemia (27.6%), thrombocytopenia (2.7%). Cardiovascular or pulmonary complications occurred in 5 (2.3%) and 22 (10%) ABVD patients, respectively, 11 of whom had undergone PET2 assessment -3 with treatment de-escalation.Conclusions: Unmet needs exist with respect to the balance between therapeutic efficacy and safety risks of 1L chemotherapies in cHL. Even when PET2 scans are available to monitor tumour response, they are not always used to modify treatment management. Most patients continue to rely on supportive care products, or experience avoidable toxicities, underscoring the importance of new treatment combinations with novel agents.

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China

“…The average BV treatment cycle was 12 in the C25010 trial. The reason to choose the 9 cycles for the base case was that the number is aligned with the finding from a review of real-world evidence, suggesting the median number of cycles ranging from 4 to 8 [ 34 ]. The number of 9 cycles was also validated by the local clinicians.…”